March brought the momentum the market has been building toward. After a slow start to the year, biotech is finally starting to defrost. M&A activity is picking up, hiring remains active across clinical and regulatory functions, and investors are re-engaging.  

At Trebla, we felt that shift firsthand with new partnerships, continued growth, and a strong pipeline of talent.

February is the month of love, which means everyone is searching for “the one.” In biotech, that looks like the Regulatory leader who has shepherded approvals, the Clinical physician who has delivered pivotal studies, and the Safety MD who keeps programs on track and risk contained. 

The catch? They’re not waiting around. February’s market is moving quickly, and the strongest matches are getting secured early. 

This month tested the biotech and pharma market, but history reminds us that recoveries are even more powerful. Market shifts and challenges spark reinvention, sharpen focus, and fuel the next wave of breakthroughs! What doesn’t kill us makes us stronger.